No Data
Little Excitement Around Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Revenues As Shares Take 27% Pounding
Earnings Preview: AYTU to Report Financial Results Post-market on November 13
$Aytu BioPharma(AYTU.US)$ is scheduled to release its financial results post-market on November 13 ET. Earnings PreviewAnalysts estimate $Aytu BioPharma(AYTU.US)$ to post revenue of USD13.77M for 2025
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
Express News | Aytu Biopharma Inc: Lupin to Seek Local Regulatory Approvals & Marketing Authorizations for Adzenys Xr-Odt & Cotempla Xr-Over Next 18 to 24 Months.
Aytu BioPharma Announces Exclusive Agreement With Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
No Data
No Data